| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Daniel García-Ovejero, Ángel Arévalo-Martín, Beatriz Navarro-Galve, Emmanuel Pinteaux, Eduardo Molina-Holgado, Francisco Molina-Holgad. Neuroimmmune interactions of cannabinoids in neurogenesis: focus on interleukin-1β (IL-1β) signalling. Biochemical Society transactions. vol 41. issue 6. 2014-08-29. PMID:24256257. |
we have investigated the role of cb1 and cb2 cannabinoid receptors in the control of nsc proliferation and in the release of immunomodulators [il-1β and il-1ra (il-1 receptor antagonist)] that control nsc fate decisions. |
2014-08-29 |
2023-08-12 |
Not clear |
| Daniel García-Ovejero, Ángel Arévalo-Martín, Beatriz Navarro-Galve, Emmanuel Pinteaux, Eduardo Molina-Holgado, Francisco Molina-Holgad. Neuroimmmune interactions of cannabinoids in neurogenesis: focus on interleukin-1β (IL-1β) signalling. Biochemical Society transactions. vol 41. issue 6. 2014-08-29. PMID:24256257. |
pharmacological blockade of cb1 and/or cb2 cannabinoid receptors abolish or decrease nsc proliferation, indicating a critical role for both cb1 and cb2 receptors in the proliferation of nsc via il-1 signalling pathways. |
2014-08-29 |
2023-08-12 |
Not clear |
| Monika Buraczynska, Piotr Wacinski, Pawel Zukowski, Michal Dragan, Andrzej Ksiaze. Common polymorphism in the cannabinoid type 1 receptor gene (CNR1) is associated with microvascular complications in type 2 diabetes. Journal of diabetes and its complications. vol 28. issue 1. 2014-08-27. PMID:24075694. |
endocannabinoids exert their biological effects via interaction with g-protein coupled cannabinoid receptors cb1 and cb2. |
2014-08-27 |
2023-08-12 |
human |
| Jenny L Wiley, Julie A Marusich, Timothy W Lefever, Megan Grabenauer, Katherine N Moore, Brian F Thoma. Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles. Neuropharmacology. vol 75. 2014-08-19. PMID:23916483. |
similar to other psychoactive cannabinoid agonists, xlr-11 and ur-144 showed low nanomolar (<30) affinity for cb1 and cb2 receptors, activated these receptors as full agonists, and produced dose-dependent effects that were blocked by rimonabant in mice, including antinociception, hypothermia, catalepsy and suppression of locomotor activity. |
2014-08-19 |
2023-08-12 |
mouse |
| Francisco Espejo-Porras, Javier Fernández-Ruiz, Roger G Pertwee, Raphael Mechoulam, Concepción Garcí. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Neuropharmacology. vol 75. 2014-08-19. PMID:23924692. |
the broad presence of cb1 receptors in the basal ganglia, mainly in gaba- or glutamate-containing neurons, as well as the presence of trpv1 receptors in dopaminergic neurons and the identification of cb2 receptors in some neuronal subpopulations within the basal ganglia, explain the powerful motor effects exerted by those cannabinoids that can activate/block these receptors. |
2014-08-19 |
2023-08-12 |
rat |
| Francisco Espejo-Porras, Javier Fernández-Ruiz, Roger G Pertwee, Raphael Mechoulam, Concepción Garcí. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Neuropharmacology. vol 75. 2014-08-19. PMID:23924692. |
by contrast, cannabidiol (cbd), a phytocannabinoid with a broad therapeutic profile, is generally presented as an example of a cannabinoid compound with no motor effects due to its poor affinity for the cb1 and the cb2 receptor, despite its activity at the trpv1 receptor. |
2014-08-19 |
2023-08-12 |
rat |
| Rebecca Hartzell Robinson, Joseph J Meissler, Jessica M Breslow-Deckman, John Gaughan, Martin W Adler, Toby K Eisenstei. Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 8. issue 5. 2014-08-18. PMID:23824763. |
cannabinoid receptor 2 (cb2) is expressed mainly on leukocytes and is the receptor implicated in mediating many of the effects of cannabinoids on immune processes. |
2014-08-18 |
2023-08-12 |
mouse |
| Rebecca Hartzell Robinson, Joseph J Meissler, Jessica M Breslow-Deckman, John Gaughan, Martin W Adler, Toby K Eisenstei. Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 8. issue 5. 2014-08-18. PMID:23824763. |
t-cell function was decreased by the cb2 agonists, as an elisa of mlr culture supernatants revealed il-2 release was significantly decreased in the cannabinoid treated cells. |
2014-08-18 |
2023-08-12 |
mouse |
| Ewa Kozela, Ana Juknat, Nathali Kaushansky, Neta Rimmerman, Avraham Ben-Nun, Zvi Voge. Cannabinoids decrease the th17 inflammatory autoimmune phenotype. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 8. issue 5. 2014-08-18. PMID:23892791. |
the downregulation of il-17 secretion by these cannabinoids does not seem to involve the cb1, cb2, pparγ, 5-ht1a or trpv1 receptors. |
2014-08-18 |
2023-08-12 |
mouse |
| Anna Maria Malfitano, Chiara Laezza, Giuseppe Saccomanni, Tiziano Tuccinardi, Clementina Manera, Adriano Martinelli, Elena Ciaglia, Simona Pisanti, Mario Vitale, Patrizia Gazzerro, Maurizio Bifulc. Immune-modulation and properties of absorption and blood brain barrier permeability of 1,8-naphthyridine derivatives. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. vol 8. issue 5. 2014-08-18. PMID:24081326. |
considering the high selectivity at the cannabinoid cb2 receptor of recently designed 1,8-naphthyridine derivatives and the protective role of this receptor in neurological disorders, in this study we investigated the immune-modulatory and anti-inflammatory effects of these compounds as well as their potential properties of intestinal absorption and blood-brain barrier (bbb) permeability. |
2014-08-18 |
2023-08-12 |
Not clear |
| Jarogniew J Luszczki, Aleksandra Wlaz, Slawomir Karwan, Magdalena Florek-Luszczki, Stanislaw J Czuczwa. Effects of WIN 55,212-2 mesylate on the anticonvulsant action of lamotrigine, oxcarbazepine, pregabalin and topiramate against maximal electroshock-induced seizures in mice. European journal of pharmacology. vol 720. issue 1-3. 2014-08-15. PMID:24161913. |
the aim of this study was to determine the effect of win 55,212-2 mesylate (win - a non-selective cannabinoid cb1 and cb2 receptor agonist) on the protective action of four second-generation antiepileptic drugs (lamotrigine, oxcarbazepine, pregabalin and topiramate) in the mouse maximal electroshock seizure model. |
2014-08-15 |
2023-08-12 |
mouse |
| María S García-Gutiérrez, Antonio Ortega-Álvaro, Arnau Busquets-García, Jose M Pérez-Ortiz, Laura Caltana, María Jimena Ricatti, Alicia Brusco, Rafael Maldonado, Jorge Manzanare. Synaptic plasticity alterations associated with memory impairment induced by deletion of CB2 cannabinoid receptors. Neuropharmacology. vol 73. 2014-08-13. PMID:23796670. |
synaptic plasticity alterations associated with memory impairment induced by deletion of cb2 cannabinoid receptors. |
2014-08-13 |
2023-08-12 |
mouse |
| Shuxian Hu, Wen S Sheng, R Bryan Roc. CB2 receptor agonists protect human dopaminergic neurons against damage from HIV-1 gp120. PloS one. vol 8. issue 10. 2014-08-05. PMID:24147028. |
these data suggest that synthetic cannabinoids are capable of protecting human dopaminergic neurons from gp120 in a variety of ways, acting principally through the cb2 receptors and microglia. |
2014-08-05 |
2023-08-12 |
human |
| Carolina Costola-de-Souza, Alison Ribeiro, Viviane Ferraz-de-Paula, Atilio Sersun Calefi, Thiago Pinheiro Arrais Aloia, João Antonio Gimenes-Júnior, Vinicius Izidio de Almeida, Milena Lobão Pinheiro, João Palermo-Net. Monoacylglycerol lipase (MAGL) inhibition attenuates acute lung injury in mice. PloS one. vol 8. issue 10. 2014-08-05. PMID:24204926. |
thus, jzl184 increases the levels of 2-ag, an endocannabinoid that acts on the cb1 and cb2 cannabinoid receptors. |
2014-08-05 |
2023-08-12 |
mouse |
| Bruno A Marichal-Cancino, Guadalupe Manrique-Maldonado, Alain H Altamirano-Espinoza, Inna Ruiz-Salinas, Abimael González-Hernández, Antoinette Maassenvandenbrink, Carlos M Villaló. Analysis of anandamide- and lysophosphatidylinositol-induced inhibition of the vasopressor responses produced by sympathetic stimulation or noradrenaline in pithed rats. European journal of pharmacology. vol 721. issue 1-3. 2014-07-15. PMID:24076186. |
the endocannabinoid system exhibits multiple functions in cardiovascular regulation mainly by cannabinoid (cb1 and cb2) receptors, vanilloid trpv1 receptors and, probably, by the orphan g protein-coupled receptor 55 (gpr55). |
2014-07-15 |
2023-08-12 |
rat |
| Girish R Chopda, V Kiran Vemuri, Rishi Sharma, Ganesh A Thakur, Alexandros Makriyannis, Carol A Paroni. Diuretic effects of cannabinoid agonists in mice. European journal of pharmacology. vol 721. issue 1-3. 2014-07-15. PMID:24099963. |
in other studies, agonist injections were preceded by pretreatment with cannabinoid cb1 or cb2 selective antagonists, including a peripherally constrained cb1 antagonist. |
2014-07-15 |
2023-08-12 |
mouse |
| Kevin T Fitzgerald, Alvin C Bronstein, Kristin L Newquis. Marijuana poisoning. Topics in companion animal medicine. vol 28. issue 1. 2014-07-10. PMID:23796481. |
there are two specific cannabinoid receptors in humans and dogs, cb1 (primarily in central nervous system) and cb2 (peripheral tissues). |
2014-07-10 |
2023-08-12 |
human |
| Sabatino Maione, Barbara Costa, Vincenzo Di Marz. Endocannabinoids: a unique opportunity to develop multitarget analgesics. Pain. vol 154 Suppl 1. 2014-07-03. PMID:23623250. |
after 4 millennia of more or less documented history of cannabis use, the identification of cannabinoids, and of Δ(9)-tetrahydrocannabinol in particular, occurred only during the early 1960s, and the cloning of cannabinoid cb1 and cb2 receptors, as well as the discovery of endocannabinoids and their metabolic enzymes, in the 1990s. |
2014-07-03 |
2023-08-12 |
Not clear |
| Miquel Bioque, Borja García-Bueno, Karina S Macdowell, Ana Meseguer, Pilar A Saiz, Mara Parellada, Ana Gonzalez-Pinto, Roberto Rodriguez-Jimenez, Antonio Lobo, Juan C Leza, Miguel Bernard. Peripheral endocannabinoid system dysregulation in first-episode psychosis. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 38. issue 13. 2014-07-01. PMID:23822951. |
protein expression of cannabinoid receptor 2 (cb2), the protein levels of the main endocannabinoid synthesizing enzymes n-acyl phosphatidylethanolamine phospholipase (nape) and diacylglycerol lipase (dagl), and of degradation enzymes fatty acid amide hydrolase (faah) and monoacylglycerol lipase (magl) were determined by western blot analysis in peripheral blood mononuclear cells (pbmcs). |
2014-07-01 |
2023-08-12 |
human |
| Marylou V Solbrig, Yijun Fan, Paul Hazelto. Prospects for cannabinoid therapies in viral encephalitis. Brain research. vol 1537. 2014-06-25. PMID:24021420. |
using a rodent model of chronic viral encephalitis based on borna disease (bd) virus, in which 1 week treatment with the general cannabinoid win 55,212-2 has been shown to be neuroprotective (solbrig et al., 2010), we examine longer term (2 week treatment) effects of a general (cb1 and cb2) cannabinoid receptor agonist win55,212-2 (1mg/kg ip twice per day) or a specific (cb2) cannabinoid receptor agonist hu-308 (5mg/kg ip once daily) on histopathology, measures of frontostriatal neurogenesis and gliogenesis, and viral load. |
2014-06-25 |
2023-08-12 |
rat |